Dengue fever (DF), caused by dengue virus, is an arboviral disease characterized by an initial non-specific febrile illness that can sometimes progress to more severe forms manifesting capillary leaka...
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation on dengue disease is limited due to the complex nature of the virus and the variability in clinical presentations. Additionally, as a disease that predominantly affects tropical regions, systematic studies have been challenging. The lack of identified genetic factors and inheritance patterns further complicates the understanding of the disease, leading to gaps in knowledge.
The clinical features of dengue disease primarily include fever (80-99%), severe headache (80-99%), pruritus (30-79%), and skin rash (30-79%). Patients may also experience arthralgia, abdominal pain, and in severe cases, complications such as cerebral hemorrhage and thrombocytopenia. The variability in symptom presentation can lead to misdiagnosis, especially in endemic areas.
To navigate your care effectively, consider consulting an infectious disease specialist with experience in arboviral diseases. Additionally, participating in clinical trials may provide access to novel treatments. You can find information about ongoing trials at ClinicalTrials.gov. While there are currently no dedicated patient organizations, you may find support through general infectious disease forums and resources. Keeping track of your symptoms and any changes is crucial for effective management.
Currently, there is an active research landscape for dengue disease, with 51 clinical trials underway. One orphan drug is a phosphoramidate oral prodrug of a unique 6-modified purine nucleotide, which is in development. For more information on ongoing trials, you can visit ClinicalTrials.gov and search for dengue disease. This research offers hope for advancements in treatment options.
Actionable guidance for navigating care for dengue disease
To navigate your care effectively, consider consulting an infectious disease specialist with experience in arboviral diseases. Additionally, participating in clinical trials may provide access to novel treatments. You can find information about ongoing trials at ClinicalTrials.gov. While there are currently no dedicated patient organizations, you may find support through general infectious disease forums and resources. Keeping track of your symptoms and any changes is crucial for effective management.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on dengue disease is limited due to the complex nature of the virus and the variability in clinical presentations. Additionally, as a disease that predominantly affects tropical regions, systematic studies have been challenging. The lack of identified genetic factors and inheritance patterns further complicates the understanding of the disease, leading to gaps in knowledge.
The clinical features of dengue disease primarily include fever (80-99%), severe headache (80-99%), pruritus (30-79%), and skin rash (30-79%). Patients may also experience arthralgia, abdominal pain, and in severe cases, complications such as cerebral hemorrhage and thrombocytopenia. The variability in symptom presentation can lead to misdiagnosis, especially in endemic areas.
To navigate your care effectively, consider consulting an infectious disease specialist with experience in arboviral diseases. Additionally, participating in clinical trials may provide access to novel treatments. You can find information about ongoing trials at ClinicalTrials.gov. While there are currently no dedicated patient organizations, you may find support through general infectious disease forums and resources. Keeping track of your symptoms and any changes is crucial for effective management.
Currently, there is an active research landscape for dengue disease, with 51 clinical trials underway. One orphan drug is a phosphoramidate oral prodrug of a unique 6-modified purine nucleotide, which is in development. For more information on ongoing trials, you can visit ClinicalTrials.gov and search for dengue disease. This research offers hope for advancements in treatment options.
Actionable guidance for navigating care for dengue disease
To navigate your care effectively, consider consulting an infectious disease specialist with experience in arboviral diseases. Additionally, participating in clinical trials may provide access to novel treatments. You can find information about ongoing trials at ClinicalTrials.gov. While there are currently no dedicated patient organizations, you may find support through general infectious disease forums and resources. Keeping track of your symptoms and any changes is crucial for effective management.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on dengue disease is limited due to the complex nature of the virus and the variability in clinical presentations. Additionally, as a disease that predominantly affects tropical regions, systematic studies have been challenging. The lack of identified genetic factors and inheritance patterns further complicates the understanding of the disease, leading to gaps in knowledge.
The clinical features of dengue disease primarily include fever (80-99%), severe headache (80-99%), pruritus (30-79%), and skin rash (30-79%). Patients may also experience arthralgia, abdominal pain, and in severe cases, complications such as cerebral hemorrhage and thrombocytopenia. The variability in symptom presentation can lead to misdiagnosis, especially in endemic areas.
To navigate your care effectively, consider consulting an infectious disease specialist with experience in arboviral diseases. Additionally, participating in clinical trials may provide access to novel treatments. You can find information about ongoing trials at ClinicalTrials.gov. While there are currently no dedicated patient organizations, you may find support through general infectious disease forums and resources. Keeping track of your symptoms and any changes is crucial for effective management.
Currently, there is an active research landscape for dengue disease, with 51 clinical trials underway. One orphan drug is a phosphoramidate oral prodrug of a unique 6-modified purine nucleotide, which is in development. For more information on ongoing trials, you can visit ClinicalTrials.gov and search for dengue disease. This research offers hope for advancements in treatment options.
Actionable guidance for navigating care for dengue disease
To navigate your care effectively, consider consulting an infectious disease specialist with experience in arboviral diseases. Additionally, participating in clinical trials may provide access to novel treatments. You can find information about ongoing trials at ClinicalTrials.gov. While there are currently no dedicated patient organizations, you may find support through general infectious disease forums and resources. Keeping track of your symptoms and any changes is crucial for effective management.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning dengue disease
Updated Feb 17, 2011
CDC, NIH, and PAHO will hold a media briefing to discuss recent developments in dengue virus research and its epidemiology in the Americas. This event aims to raise awareness about dengue and its impact on public health.
A report indicates that nearly 5% of Key West's population, over 1,000 individuals, showed evidence of recent exposure to the dengue virus in 2009. This finding highlights the ongoing public health concern regarding dengue in the region.